Search

Your search keyword '"Vittecoq, Olivier"' showing total 694 results
Start Over Author "Vittecoq, Olivier"
694 results on '"Vittecoq, Olivier"'

1. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

Author

Nguyen, Yann, Nocturne, Gaëtane, Henry, Julien, Ng, Wan-Fai, Belkhir, Rakiba, Desmoulins, Frédéric, Bergé, Elisabeth, Morel, Jacques, Perdriger, Aleth, Dernis, Emmanuelle, Devauchelle-Pensec, Valérie, Sène, Damien, Dieudé, Philippe, Couderc, Marion, Fauchais, Anne-Laure, Larroche, Claire, Vittecoq, Olivier, Salliot, Carine, Hachulla, Eric, Le Guern, Véronique, Gottenberg, Jacques-Eric, Mariette, Xavier, and Seror, Raphaèle

Published
2024
Full Text
View/download PDF

4. The determinants associated with the prescription of a first biologic therapy in patients with axial spondyloarthritis and concomitant fibromyalgia are mostly objective and in line with the recommendations. Results of a cross-sectional survey-based study using a mixed (qualitative and quantitative) approach to help rheumatologists in their daily practice

Author

Renouprez, Thibaut, Gillibert, André, Gerard, Baptiste, Pouplin, Sophie, Marcelli, Christian, Lequerre, Thierry, Schuers, Matthieu, and Vittecoq, Olivier

Published
2024
Full Text
View/download PDF

7. Épidémiologie de l’atteinte dermatologique dans le syndrome de Sjögren : données provenant de trois populations françaises de Syndrome de Sjogren primitif (TEARS, ASSESS, diapSS)

Author

Villon, Camille, Orgeolet, Laure, Roguedas, Anne-Marie, Misery, Laurent, Gottenberg, Jacques-Eric, Cornec, Divi, Jousse-Joulin, Sandrine, Seror, Raphaele, Berthelot, Jean-Marie, Dieude, Philippe, Dubost, Jean-Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre-Yves, Larroche, Claire, Hayem, Gilles, Le Guern, Véronique, Perdriger, Aleth, Morel, Jacques, Vittecoq, Olivier, Mariette, Xavier, Devauchelle-Pensec, Valérie, and Saraux, Alain

Published
2022
Full Text
View/download PDF

8. Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review.

Author

Barat, Eric, Soubieux, Annaelle, Brevet, Pauline, Gerard, Baptiste, Vittecoq, Olivier, Lequerre, Thierry, Chenailler, Catherine, Varin, Rémi, and Lattard, Claire

Subjects
PATIENT compliance, OCCUPATIONAL roles, MEDICATION errors, CINAHL database, PATIENT care, TREATMENT effectiveness, MEDICATION reconciliation, MEDLINE, MEDICAL databases, RHEUMATOLOGY, ONLINE information services, DRUGS, MEDICAL care costs
Abstract

This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry.

Author

Nguyen, Yann, Mariette, Xavier, Gottenberg, Jacques E, Iudici, Michele, Morel, Jacques, Vittecoq, Olivier, Constantin, Arnaud, Flipo, Rene-Marc, Schaeverbeke, Thierry, Sibilia, Jean, Ravaud, Philippe, Porcher, Raphaël, and Seror, Raphaèle

Subjects
PATIENT safety, DRUG side effects, RHEUMATOID arthritis, CLINICAL trials, AUTOANTIBODIES, RITUXIMAB, TREATMENT effectiveness, ANTIRHEUMATIC agents, LONGITUDINAL method, RESEARCH, CONFIDENCE intervals, C-reactive protein
Abstract

Objectives To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. Methods The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials. We determined critical eligibility criteria and modelled the benefit–risk ratio according to the number of fulfilled critical eligibility criteria. Results Among 1984 RA patients, only 9–12% fulfilled all eligibility criteria. Non-eligible patients had fewer EULAR responses at 12 months (40.3% vs 46.9%, P  = 0.044). Critical inclusion criteria included swollen joints count ≥4, tender joints count ≥4, CRP ≥15 mg/l and RF positivity. Critical exclusion criteria were age >80 years, RA-associated systemic diseases, ACR functional class IV, DMARD other than MTX and prednisone >10 mg/day. Only 20.8% fulfilled those critical eligibility criteria. During the first year, serious AEs occurred for 182 (9.2%) patients (70.3% serious infections) and patients with ≥1 critical exclusion criterion were at higher risk (hazard ratio 3.03; 95% CI 2.25–4.06; for ≥3 criteria vs 0). The incremental risk–benefit ratio decreased with the number of unmet critical inclusion criteria and of fulfilled exclusion criteria. Conclusion Few real-life RA patients were eligible for the drug-registration trials. Non-eligible patients had lower chance of response, and higher risk of serious AEs. Efficacy and safety data obtained from those trials may not be generalizable to RA patients receiving RTX in real-world clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort

Author

Felten, Renaud, primary, Fabacher, Thibaut, additional, Sedmak, Nathanaël, additional, Sibilia, Jean, additional, Sordet, Christelle, additional, Chatelus, Emmanuel, additional, Berenbaum, Francis, additional, Combe, Bernard, additional, Ruyssen-Witrand, Adeline, additional, Vittecoq, Olivier, additional, Meyer, Nicolas, additional, and Gottenberg, Jacques-Eric, additional

Published
2024
Full Text
View/download PDF

12. Characterisation of airway disease associated with Sjögren disease

Author

Meudec, Loïc, primary, Debray, Marie-Pierre, additional, Beurnier, Antoine, additional, Marques, Cindy, additional, Juge, Pierre-Antoine, additional, Dhote, Robin, additional, Larroche, Claire, additional, Fauchais, Anne Laure, additional, Dernis, Emanuelle, additional, Vittecoq, Olivier, additional, Saraux, Alain, additional, Gottenberg, Jacques-Eric, additional, Hachulla, Eric, additional, Le Guern, Véronique, additional, Dieudé, Philippe, additional, Seror, Raphaele, additional, Mariette, Xavier, additional, and Nocturne, Gaétane, additional

Published
2024
Full Text
View/download PDF

13. Effect of Lymphoma Treatment Approaches on Hematologic Response and Autoimmune Disease Activity in Sjögren's Patients with Lymphoma

Author

Rocca, Juliette, primary, Beydon, Maxime, additional, Le Guern, Véronique, additional, Hachulla, Eric, additional, Couderc, Marion, additional, Jousse-Joulin, Sandrine, additional, Devauchelle-Pensec, Valérie, additional, Gottenberg, Jacques-Eric, additional, Vittecoq, Olivier, additional, Lavigne, Christian, additional, Schmidt, Jean, additional, Larroche, Claire, additional, Mariette, Xavier, additional, Seror, Raphaèle, additional, and Nocturne, Gaetane, additional

Published
2024
Full Text
View/download PDF

14. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)

Author

Villon, Camille, Orgeolet, Laure, Roguedas, Anne-Marie, Misery, Laurent, Gottenberg, Jacques-Eric, Cornec, Divi, Jousse-Joulin, Sandrine, Seror, Raphaele, Berthelot, Jean-Marie, Dieude, Philippe, Dubost, Jean-Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre-Yves, Larroche, Claire, Hayem, Gilles, Le Guern, Véronique, Perdriger, Aleth, Morel, Jacques, Vittecoq, Olivier, Mariette, Xavier, Devauchelle-Pensec, Valérie, and Saraux, Alain

Published
2021
Full Text
View/download PDF

16. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials

Author

Devauchelle-Pensec, Valerie, Dieude, Philippe, Dubost, Jean Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Larroche, Claire, Le Guern, Véronique, Morel, Jacques, Perdriger, Aleth, Puéchal, Xavier, Rist, Stephanie, Sen, Damien, Sibilia, Jean, Vittecoq, Olivier, Benessiano, Joelle, Tubiana, Sarah, Inamo, Karine, Gaete, Stanie, Batouche, Djilali, Molinari, Domitille, Randrianandrasana, Mickael, Pane, Isabelle, Abbe, Adeline, Baron, Gabriel, Ravaud, Philippe, Gottenberg, Jacques-Eric, Saraux, Alain, Devauchelle-Pensec, Valérie, Hayem, Gilles, Hatron, Pierre, Sene, Damien, Zarnitsky, Charles, Furlan, Valérie, Perrodeau, Elodie, Seror, Raphaele, Mariette, Xavier, Brown, S, Navarro, N Coy, Pitzalis, C, Emery, P, Pavitt, S, Gray, J, Hulme, C, Hall, F, Busch, R, Smith, P, Dawson, L, Bombardieri, M, Ng, W-F, Pease, C, Price, E, Sutcliffe, N, Woods, C, Ruddock, S, Everett, C, Reynolds, C, Skinner, E, Poveda-Gallego, A, Rout, J, Macleod, I, Rauz, S, Bowman, S, Ng, Wan-Fai, Bowman, Simon J, Griffiths, Bridget, Hall, Frances, Bacaba, Elalaine C, Frankland, Helen, Moots, Robert, Chadravarty, Kuntal, Lamabadusuriya, Shamin, Bombardieri, Michele, Pitzalis, Constantino, Sutcliffe, Nurhan, Breston, Celia, Gendi, Nagui, Culfear, Karen, Riddell, Claire, Hamburger, John, Richards, Andrea, Rauz, Saaeh, Brailsford, Sue, Dasgin, Joanne, Logan, Joanne, Mulherin, Diarmuid, Andrews, Jacqueline, Emery, Pau, McManus, Alison, Pease, Colin, Pickles, David, Booth, Alison, Regan, Marian, Kin, Jon King, Holt, Amanda, Dimitroulas, Theodoros, Kadiki, Lucy, Kaur, Daljit, Kitas, George, Khan, Abdul, Cosier, Tracey, Panthakalam, Mintrim, Kell, Lloyd, Mark, Moore, Lisa, Gordon, Esther, Lawson, Cathy, Gupta, Monica, Hunter, John, Stirton, Lesley, Ortiz, Gill, Price, Elizabeth, Pelger, Suzannah, Gorman, Claire, Hans, Balinder, Clunie, Gavin, Lane, Suzanne, Rose, Ginny, Cuckow, Sue, Batley, Michael, Einosas, Ruby, Knight, Susan, Symmons, Deborah, Jones, Beverley, Carr, Andrew, Edgar, Suzanne, Figuereido, Francisco, Foggo, Heather, Lendrem, Dennis, Macleod, Iain, Mitchell, Sheryl, Downie, Christine, Tarn, Jessica, Locke, James, Al-Ali, Shereen, Legg, Sarah, Mirza, Kamran, Hargreaves, Ben, Hetherington, Laura, Jones, Adrian, Lanyon, Peter, Muir, Alice, White, Paula, Young-Min, Steven, Pugmire, Susan, Vadivelu, Saravanan, Cooper, Annie, Watkins, Marianne, Field, Anne, Kaye, Stephen, Mewar, Devesh, Medcalf, Patricia, Tomlinson, Pamela, Whiteside, Debbie, McHugh, Neil, Pauling, John, James, Julie, Dowden, Andrea, Akil, Mohammed, McDermott, Jayne, Godia, Olivia, Coady, David, Kidd, Elizabeth, Palmer, Lynne, Li, Charles, Bartrum, Sarah, Mead, De, Dasgupta, Bhaskar, Katsande, Victoria, Long, Pamela, Vermaak, Erin, Turner, Janet, Chandra, Usha, MacKay, Kirsten, Fedele, Stefano, Ferenkeh-Koroma, Ada, Giles, Ian, Isenberg, David, MaConnell, Helena, Ahwiren, Nyarko, Porter, Stephen, Allcoa, Paul, McLaren, John, Tarn, Jessica R, Howard-Tripp, Nadia, Lendrem, Dennis W, Skelton, Andrew J, James, Katherine, McMeekin, Peter, Hackett, Katie L, Lendrem, B Clare, Casement, John, Pease, Colin T, Emery, Paul, Pitzalis, Costantino, Saravanan, Vadivelu, Johnsen, Svein J A, Norheim, Katrine B, Omdal, Roald, Stocken, Deborah, Everett, Colin, Fernandez, Catherine, and Isaacs, John D

Published
2019
Full Text
View/download PDF

23. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry

Author

Nguyen, Yann, primary, Mariette, Xavier, additional, Gottenberg, Jacques E, additional, Iudici, Michele, additional, Morel, Jacques, additional, Vittecoq, Olivier, additional, Constantin, Arnaud, additional, Flipo, Rene-Marc, additional, Schaeverbeke, Thierry, additional, Sibilia, Jean, additional, Ravaud, Philippe, additional, Porcher, Raphaël, additional, and Seror, Raphaèle, additional

Published
2023
Full Text
View/download PDF

26. Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases

Author

Lebel, Nans, primary, Marie, Isabelle, additional, Grosjean, Julien, additional, Brevet, Pauline, additional, Leclercq, Mathilde, additional, Dumont, Anaël, additional, Levesque, Hervé, additional, Benhamou, Ygal, additional, Marcelli, Christian, additional, Lequerre, Thierry, additional, and Vittecoq, Olivier, additional

Published
2023
Full Text
View/download PDF

36. A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease

Author

Juge, Pierre‐Antoine, primary, Granger, Benjamin, additional, Debray, Marie‐Pierre, additional, Ebstein, Esther, additional, Louis‐Sidney, Fabienne, additional, Kedra, Joanna, additional, Doyle, Tracy J., additional, Borie, Raphaël, additional, Constantin, Arnaud, additional, Combe, Bernard, additional, Flipo, René‐Marc, additional, Mariette, Xavier, additional, Vittecoq, Olivier, additional, Saraux, Alain, additional, Carvajal‐Alegria, Guillermo, additional, Sibilia, Jean, additional, Berenbaum, Francis, additional, Kannengiesser, Caroline, additional, Boileau, Catherine, additional, Sparks, Jeffrey A., additional, Crestani, Bruno, additional, Fautrel, Bruno, additional, and Dieudé, Philippe, additional

Published
2022
Full Text
View/download PDF

39. Biologic targeted therapies in pediatric rheumatology

Author

Guillaume-Czitrom, Séverine, Bachelez, Hervé, Berthelot, Jean-Marie, Bouhnik, Yoram, Bruckert, Eric, Claudepierre, Pascal, Constantin, Arnaud, de Bandt, Michel, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Gottenberg, Jacques-Eric, Goupille, Philippe, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemannf, Marc, Lequerré, Thierry, Maillefert, Jean-Francis, Mariette, Xavier, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pham, Thao, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Sellam, Jérémie, Blacher, Jacques, Soubrier, Martin, Sudre, Anne, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, and Sibilia, Jean

Published
2014
Full Text
View/download PDF

41. Variability of Primary Sjögren's Syndrome Is Driven by Interferon α and Interferon α Blood Levels Are Associated With the Class II HLA–DQ Locus

Author

Trutschel, Diana, Bost, Pierre, Mariette, Xavier, Bondet, Vincent, Llibre, Alba, Posseme, Celine, Charbit, Bruno, Thorball, Christian W., Jonsson, Roland, Lessard, Christopher J., Felten, Renaud, Ng, Wan Fai, Chatenoud, Lucienne, Dumortier, Hélène, Sibilia, Jean, Fellay, Jacques, Brokstad, Karl A., Appel, Silke, Tarn, Jessica R., Quintana‐Murci, Lluis, Mingueneau, Michael, Meyer, Nicolas, Duffy, Darragh, Schwikowski, Benno, Gottenberg, Jacques Eric, Dernis, Emmanuelle, Devauchelle‐Pensec, Valerie, Dieude, Philippe, Dubost, Jean‐Jacques, Fauchais, Anne‐Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre Yves, Larroche, Claire, Le Guern, Véronique, Morel, Jacques, Perdriger, Aleth, Salliot, Carinne, Rist, Stephanie, Saraux, Alain, Vittecoq, Olivier, Nocturne, Gaétane, Ravaud, Philippe, Seror, Raphaèle, Abel, Laurent, Alcover, Andres, Aschard, Hugues, Astrom, Kalla, Bousso, Philippe, Bruhns, Pierre, Cumano, Ana, Demangel, Caroline, Deriano, Ludovic, Di Santo, James, Dromer, Françoise, Eberl, Gérard, Enninga, Jost, Gelpi, Odile, GompertsBoneca, Ivo, Hasan, Milena, Hercberg, Serge, Lantz, Olivier, Leclerc, Claude, Mouquet, Hugo, Pellegrini, Sandra, Pol, Stanislas, Rausell, Antonio, Rogge, Lars, Sakuntabhai, Anavaj, Schwartz, Olivier, Shorte, Spencer, Soumelis, Vassili, Tangy, Frédéric, Tartour, Eric, Toubert, Antoine, Touvier, Mathilde, Ungeheuer, Marie‐Noëlle, Albert, Matthew L., Biomédecine computationelle des systèmes / Computational systems biomedicine, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Universität Zürich [Zürich] = University of Zurich (UZH), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Projet NECESSITY (PN), Hôpitaux Universitaires Paris Sud [AP-HP] (HUPS)-Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie Translationnelle - Translational Immunology lab, Cytometrie et Biomarqueurs – Cytometry and Biomarkers (UTechS CB), Ecole Polytechnique Fédérale de Lausanne (EPFL), Université de Lausanne = University of Lausanne (UNIL), Lausanne University Hospital, University of Bergen (UiB), Oklahoma Medical Research Foundation (OMRF), University of Oklahoma Health Sciences Center (OUHSC), Université de Strasbourg (UNISTRA), Institut de biologie moléculaire et cellulaire (IBMC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Newcastle University [Newcastle], Newcastle Upon Tyne Hospitals NHS Foundation Trust, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Génétique Evolutive Humaine - Human Evolutionary Genetics, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Biogen Inc. [Cambridge, MA, USA], Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant 806975). The JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Unionand the European Federation of Pharmaceutical Industries and Associations. This work was also supported by the National Institutes of Health (National Institute of Arthritis and Musculoskeletal Skin Disease grant R01-AR-065953). The Assessment of Systemic Signs and Evolution in Sjögren’s Syndrome(ASSESS) national multicenter prospective cohort was formed in 2006 with aFrench Ministry of Health grant (Programme Hospitalier de Recherche Clinique 2005 P060228). The ASSESS cohort is promoted by the French Society of Rheumatology and receives research grants from the French Society of Rheumatology. Dr. Gottenberg’s work was supported by Bristol Myers Squibbfor transcriptomic analysis of the ASSESS and Norwegian cohorts and by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögrenet des syndromes secs). Drs. Trutschel’s and Schwikowski’s work was supported by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögren et des syndromes secs)., Milieu Intérieur Consortium, ASSESS study investigators, and NECESSITY Consortium: Emmanuelle Dernis, Valerie Devauchelle-Pensec, Philippe Dieude, Jean-Jacques Dubost, Anne-Laure Fauchais, Vincent Goeb, Eric Hachulla, Pierre Yves Hatron, Claire Larroche, Véronique Le Guern, Jacques Morel, Aleth Perdriger, Carinne Salliot, Stephanie Rist, Alain Saraux, Jean Sibilia, Olivier Vittecoq, Gaétane Nocturne, Philippe Ravaud, Raphaèle Seror, Laurent Abel, Andres Alcover, Hugues Aschard, Kalla Astrom, Philippe Bousso, Pierre Bruhns, Ana Cumano, Caroline Demangel, Ludovic Deriano, James Di Santo, Françoise Dromer, Gérard Eberl, Jost Enninga, Jacques Fellay, Odile Gelpi, Ivo GompertsBoneca, Milena Hasan, Serge Hercberg, Olivier Lantz, Claude Leclerc, Hugo Mouquet, Sandra Pellegrini, Stanislas Pol, Antonio Rausell, Lars Rogge, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Vassili Soumelis, Frédéric Tangy, Eric Tartour, Antoine Toubert, Mathilde Touvier, Marie-Noëlle Ungeheuer, Matthew L Albert, Darragh Duffy, Lluis Quintana-Murci., European Project: 806975,NECESSITY, Clauss, Isabelle, and NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients - NECESSITY - 0000-00-00 - 0000-00-00 - 806975 - VALID

Subjects
Proteomics, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Sjogren's Syndrome, Rheumatology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, HLA-DQ Antigens, Immunology, Humans, Interferon-alpha, Immunology and Allergy, Prospective Studies
Abstract

Objective: Primary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptomic, proteomic, cellular, and genetic data with clinical phenotypes in a cohort of 351 patients with primary SS. Methods: We analyzed blood transcriptomes and genotypes of 351 patients with primary SS who were participants in a multicenter prospective clinical cohort. We replicated the transcriptome analysis in 3 independent cohorts (n = 462 patients). We determined circulating interferon-α (IFNα) and IFNγ protein concentrations using digital single molecular arrays (Simoa). Results: Transcriptome analysis of the prospective cohort showed a strong IFN gene signature in more than half of the patients; this finding was replicated in the 3 independent cohorts. Because gene expression analysis did not discriminate between type I IFN and type II IFN, we used Simoa to demonstrate that the IFN transcriptomic signature was driven by circulating IFNα and not by IFNγ protein levels. IFNα protein levels, detectable in 75% of patients, were significantly associated with clinical and immunologic features of primary SS disease activity at enrollment and with increased frequency of systemic complications over the 5-year follow-up. Genetic analysis revealed a significant association between IFNα protein levels, a major histocompatibility (MHC) class II haplotype, and anti-SSA antibody. Additional cellular analysis revealed that an MHC class II HLA–DQ locus acts through up-regulation of HLA class II molecules on conventional dendritic cells. Conclusion: We identified the predominance of IFNα as a driver of primary SS variability, with IFNα demonstrating an association with HLA gene polymorphisms., Arthritis & Rheumatology, 74 (12), ISSN:2326-5191, ISSN:2326-5205

Published
2022

43. Clinical and ultrasonographic evaluation of the window of opportunity for retreatment with rituximab in rheumatoid arthritis patients from a multicentre real-life study

Author

Vittecoq, Olivier, primary, Kozyreff-Meurice, Marie, additional, Houivet, Estelle, additional, Leon, Nathalie, additional, Berard, Laure, additional, Gauthier-Prieur, Maud, additional, Pouplin, Sophie, additional, Avenel, Gilles, additional, Brevet, Pauline, additional, Benichou, Jacques, additional, Michelin, Paul, additional, Marcelli, Christian, additional, and Lequerre, Thierry, additional

Published
2022
Full Text
View/download PDF

48. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy – A pilot study from the VErA cohort

Author

Lanfant-Weybel, Karine, Michot, Chantal, Daveau, Romain, Milliez, Pierre-Yves, Auquit-Auckbur, Isabelle, Fardellone, Patrice, Brazier, Michel, Mejjad, Othmane, Daragon, Alain, Krzanowska, Kataryna, Jouen, Fabienne, Tron, François, Le Loarer, François, Le Loët, Xavier, and Vittecoq, Olivier

Published
2012
Full Text
View/download PDF

50. L’expression synoviale de CD20 représente un nouveau facteur prédictif potentiel de la progression des érosions osseuses lors d’une arthrite très récente traitée par DMARD en monothérapie séquentielle – étude pilote à partir de la cohorte VErA

Author

Lanfant-Weybel, Karine, Michot, Chantal, Daveau, Romain, Milliez, Pierre-Yves, Auquit-Auckbur, Isabelle, Fardellone, Patrice, Brazier, Michel, Mejjad, Othmane, Daragon, Alain, Krzanowska, Kataryna, Jouen, Fabienne, Tron, François, Le Loarer, François, Le Loët, Xavier, and Vittecoq, Olivier

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results